Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

EMA Recommends Extension of Therapeutic Indications for Epcoritamab
Дата публикации: 24-07-2026 07:07:00

New indication concerns a combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1EMA Recommends Extension of Therapeutic Indications for Serplulimab013.8831-07-2026
2EMA Recommends Extension of Therapeutic Indications for Cetuximab011.314-08-2026
3EMA Recommends Extension of Therapeutic Indications for Encorafenib0503-07-2026
4EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin0519-06-2026
5EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan0510-07-2026
6EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength09.6407-08-2026
7Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL014.7606-08-2026
8FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC013.1329-07-2026
9FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies014.5912-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 8.04. Источник: www.esmo.org.